Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
Joint Authors
Li, Jiangtao
Shi, Guixiu
Lu, Yanrong
Yang, Nanping
Mao, Hejuan
Chen, Shuo
Liang, Yan
Source
Clinical and Developmental Immunology
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-16, 16 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-11-26
Country of Publication
Egypt
No. of Pages
16
Main Subjects
Abstract EN
All randomized controlled trials (RCTs) of iguratimod for rheumatoid arthritis (RA) to assess its efficacy and safety are included in this paper.
The Review Manager software was used for meta-analysis to assess risk bias of the studies included, and GRADE profiler software was used for the evidence quality of the studies included.
Four RCTs involving 1407 patients with RA were included.
Meta-analyses showed that, after 24-week therapy, ACR20, tender joint count, swollen joint count, rest pain, physician and patient global assessment of disease activity, HAQ score, ESR, and CRP in iguratimod group were better than those in placebo group and that the difference between those of iguratimod group and those of other DMARDs (MTX and SASP) group was not significant.
GRADE evidence classification of the studies included was moderate.
Iguratimod for RA had few adverse events, and its efficacy and safety were the same as those of MTX and SASP for RA.
The results of this systematic review suggest that more high-quality and large-scaled RCTs were needed to determine the efficacy of iguratimod for RA and whether iguratimod is as effective as other DMARDs besides MTX and SASP.
American Psychological Association (APA)
Li, Jiangtao& Mao, Hejuan& Liang, Yan& Lu, Yanrong& Chen, Shuo& Yang, Nanping…[et al.]. 2013. Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis. Clinical and Developmental Immunology،Vol. 2013, no. 2013, pp.1-16.
https://search.emarefa.net/detail/BIM-462468
Modern Language Association (MLA)
Li, Jiangtao…[et al.]. Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis. Clinical and Developmental Immunology No. 2013 (2013), pp.1-16.
https://search.emarefa.net/detail/BIM-462468
American Medical Association (AMA)
Li, Jiangtao& Mao, Hejuan& Liang, Yan& Lu, Yanrong& Chen, Shuo& Yang, Nanping…[et al.]. Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis. Clinical and Developmental Immunology. 2013. Vol. 2013, no. 2013, pp.1-16.
https://search.emarefa.net/detail/BIM-462468
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-462468